Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics

Xu Zhang1, Natalya Belkina, Harrys Kishore Charles Jacob

  • 1Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Proteomics
|November 19, 2014
PubMed

Insights

This study identifies key phosphorylation targets affected by mutant epidermal growth factor receptor (EGFR) in lung adenocarcinoma. It reveals how erlotinib treatment impacts signaling pathways in TKI-sensitive versus TKI-resistant cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Mutations in the epidermal growth factor receptor (EGFR) kinase domain are common in lung adenocarcinoma, influencing sensitivity to tyrosine kinase inhibitors (TKIs).
  • Understanding the downstream phosphorylation events regulated by mutant EGFR is crucial for developing effective targeted therapies.

Purpose of the Study:

  • To identify the immediate direct and indirect phosphorylation targets of mutant EGFRs in lung adenocarcinoma.
  • To compare the phosphorylation changes in TKI-sensitive versus TKI-resistant lung adenocarcinoma cells upon erlotinib treatment.

Main Methods:

  • Utilized SILAC (Stable Isotope Labeling by Amino acids in Cell culture) strategy for quantitative proteomics.
  • Employed phosphopeptide enrichment and mass spectrometry (MS) to identify dynamic phosphorylation changes.
  • Analyzed signaling pathways and kinase-substrate relationships affected by mutant EGFR and TKI treatment.

Main Results:

  • Identified distinct phosphorylation patterns downstream of TKI-sensitive (EGFR(L858R)) and TKI-resistant (EGFR(L858R/T790M)) mutations.
  • Erlotinib treatment inhibited key signaling pathways (EGFR, MAPK, mTOR, JAK/STAT) in sensitive cells but not in resistant cells.
  • Discovered constitutive phosphorylation of ULK1 (S623) in the autophagy network, which was sensitive to erlotinib in sensitive cells.

Conclusions:

  • This study provides the first global view of phosphorylation changes upon erlotinib treatment in lung adenocarcinoma cells with mutant EGFR.
  • The findings offer new insights into the signaling networks regulated by mutant EGFR, differentiating between TKI-sensitive and TKI-resistant phenotypes.
  • The data highlights potential therapeutic targets and mechanisms of resistance in EGFR-mutated lung adenocarcinoma.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.2K